FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1854328744> ?p ?o ?g. }

• W1854328744 endingPage "20" @default.
• W1854328744 startingPage "4413" @default.
• W1854328744 abstract "Abstract The purpose of this study was to ascertain time-dose relationships for 5-fluorouracil (5-FUra) cytotoxicity against a variety of human epithelial cancer cells in vitro . Three human colon adenocarcinomas (HT-29/SP-1, LoVo/SP-1, Colo 205), two human cervix carcinomas (HeLa, Me-180-VC1), and one human ovary carcinoma (Ovary 2008-VC1) were examined for their clonogenic capacity following various 5-FUra treatment regimens. The 5-FUra regimens ranged from traditional bolusequivalent concentrations (25 to 500 µg/ml) administered for 1 hr (approximate complete serum clearance time) to clinically achievable infusion concentrations (1.0 µg/ml) administered for 72 hr. The time-dose relationships obtained in this manner indicated that: ( a ) relatively high drug concentrations are required for pulse exposures of 5-FUra to be cytocidal against these human cancer cells and that human cell sensitivity even within the same tissue type can vary significantly under these conditions (range of doses lethal to 50% of the cells, 30 to 120 µg/ml); ( b ) tremendous reductions in cell survival can be produced by a very restricted 5-FUra dose range (1 to 4 µg/ml) if exposure times are extended beyond the cell cycle time. The data suggest that human cell sensitivities to 5-FUra exhibit less variation under prolonged infusion regimens (72-hr range of doses lethal to 50% of the cells, 0.5 to 1.0 µg/ml). The 5-FUra time-dose relationships are discussed with regard to patient serum clearance times for bolus versus infusion 5-FUra clinical regimens. Our most important conclusions are that the 5-FUra concentrations necessary to achieve a level of cell toxicity for these same lines for exposures of 1 full hr are probably not clinically achievable by bolus 5-FUra therapy administrations. These experiments suggest that, when 5-FUra is administered at lower doses for longer time periods, it is more effective in producing direct cytotoxic effects in human tumor cells than when administered at higher doses for shorter times." @default.
• W1854328744 created "2016-06-24" @default.
• W1854328744 creator A5040758161 @default.
• W1854328744 creator A5045213541 @default.
• W1854328744 creator A5051786644 @default.
• W1854328744 creator A5082198675 @default.
• W1854328744 date "1982-11-01" @default.
• W1854328744 modified "2023-09-23" @default.
• W1854328744 title "Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro." @default.
• W1854328744 cites W1480773154 @default.
• W1854328744 cites W1504496277 @default.
• W1854328744 cites W1522357622 @default.
• W1854328744 cites W1575223772 @default.
• W1854328744 cites W1631165342 @default.
• W1854328744 cites W1823234971 @default.
• W1854328744 cites W1876804437 @default.
• W1854328744 cites W1893512222 @default.
• W1854328744 cites W1967995815 @default.
• W1854328744 cites W1970244282 @default.
• W1854328744 cites W1977170769 @default.
• W1854328744 cites W1994593324 @default.
• W1854328744 cites W1998069961 @default.
• W1854328744 cites W2021776239 @default.
• W1854328744 cites W2023034900 @default.
• W1854328744 cites W2025022702 @default.
• W1854328744 cites W2032178037 @default.
• W1854328744 cites W2033206022 @default.
• W1854328744 cites W2033608691 @default.
• W1854328744 cites W2038550728 @default.
• W1854328744 cites W2039236968 @default.
• W1854328744 cites W2042757811 @default.
• W1854328744 cites W2047510518 @default.
• W1854328744 cites W2055983050 @default.
• W1854328744 cites W2079118734 @default.
• W1854328744 cites W2098595207 @default.
• W1854328744 cites W2131728068 @default.
• W1854328744 cites W2147853288 @default.
• W1854328744 cites W2157125980 @default.
• W1854328744 cites W2166145186 @default.
• W1854328744 cites W2410387248 @default.
• W1854328744 cites W2415076282 @default.
• W1854328744 cites W2419392684 @default.
• W1854328744 cites W616358053 @default.
• W1854328744 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7127282" @default.
• W1854328744 hasPublicationYear "1982" @default.
• W1854328744 type Work @default.
• W1854328744 sameAs 1854328744 @default.
• W1854328744 citedByCount "50" @default.
• W1854328744 countsByYear W18543287442014 @default.
• W1854328744 countsByYear W18543287442017 @default.
• W1854328744 countsByYear W18543287442018 @default.
• W1854328744 countsByYear W18543287442019 @default.
• W1854328744 countsByYear W18543287442020 @default.
• W1854328744 countsByYear W18543287442022 @default.
• W1854328744 crossrefType "journal-article" @default.
• W1854328744 hasAuthorship W1854328744A5040758161 @default.
• W1854328744 hasAuthorship W1854328744A5045213541 @default.
• W1854328744 hasAuthorship W1854328744A5051786644 @default.
• W1854328744 hasAuthorship W1854328744A5082198675 @default.
• W1854328744 hasConcept C109316439 @default.
• W1854328744 hasConcept C117262875 @default.
• W1854328744 hasConcept C121608353 @default.
• W1854328744 hasConcept C126322002 @default.
• W1854328744 hasConcept C202751555 @default.
• W1854328744 hasConcept C203014093 @default.
• W1854328744 hasConcept C2777366897 @default.
• W1854328744 hasConcept C2777546739 @default.
• W1854328744 hasConcept C2780456651 @default.
• W1854328744 hasConcept C55493867 @default.
• W1854328744 hasConcept C71924100 @default.
• W1854328744 hasConcept C86803240 @default.
• W1854328744 hasConcept C96232424 @default.
• W1854328744 hasConcept C98274493 @default.
• W1854328744 hasConceptScore W1854328744C109316439 @default.
• W1854328744 hasConceptScore W1854328744C117262875 @default.
• W1854328744 hasConceptScore W1854328744C121608353 @default.
• W1854328744 hasConceptScore W1854328744C126322002 @default.
• W1854328744 hasConceptScore W1854328744C202751555 @default.
• W1854328744 hasConceptScore W1854328744C203014093 @default.
• W1854328744 hasConceptScore W1854328744C2777366897 @default.
• W1854328744 hasConceptScore W1854328744C2777546739 @default.
• W1854328744 hasConceptScore W1854328744C2780456651 @default.
• W1854328744 hasConceptScore W1854328744C55493867 @default.
• W1854328744 hasConceptScore W1854328744C71924100 @default.
• W1854328744 hasConceptScore W1854328744C86803240 @default.
• W1854328744 hasConceptScore W1854328744C96232424 @default.
• W1854328744 hasConceptScore W1854328744C98274493 @default.
• W1854328744 hasIssue "11" @default.
• W1854328744 hasLocation W18543287441 @default.
• W1854328744 hasOpenAccess W1854328744 @default.
• W1854328744 hasPrimaryLocation W18543287441 @default.
• W1854328744 hasRelatedWork W1854328744 @default.
• W1854328744 hasRelatedWork W2037394566 @default.
• W1854328744 hasRelatedWork W2131728068 @default.
• W1854328744 hasRelatedWork W2240764259 @default.
• W1854328744 hasRelatedWork W2282957783 @default.
• W1854328744 hasRelatedWork W2286331521 @default.
• W1854328744 hasRelatedWork W3113330825 @default.

• next